Bitter Pills:Medicines & The Third World Poor | Page 228
73
Aspirin, chlorpromazine, ferrous sulphate, piperazine, analgin (aspirin + phenaeetin + caffe
-ine -H codeine phosphate).
74
Advertisement appeared, for example, in Indian Express, 29 December 1980, and India Today,
1-15 February 1981.
75
Theo Fergusson, Manager Quality Control Laboratory, Lesotho Dispensary Association,
personal communication, 2 July 1980.
76
WHO, NIEO and Health, Annex 3 (unpublished draft paper), May 1980.
77
WHO, "Quality assurance of drugs in multi-source purchasing", p.22. (unpublished draft
1980)
78
R.K.Menda, President of the Indian Medical Association, "The ethics of the Drug Industry",
Business India, 7-20 July 1980.
79
UNCTAD Case Studies in Transfer of Technology: Pharmaceutical Products in Sri Lanka,
1977, op.cit.
80
Bangladesh Prescriber's Guide 79, pp. 19-20.
81
UNCTC, 1979, op.cit.
82
Pharmacist J.V. Tapster, letter to the Daily Telegraph, 13 December 1979.
83
U NCT A D, Case Studies in the Transfer of Technology: Pharamceuticalpolicies in Sri Lanka,
1977, op.cit.
84
UNCTC, "Case Study on India", draft report on "Transnational Corporations in the
pharmaceutical industry of developing countries',' 9 February 1981.
85
WHO Regional Office for the Western Pacific, Reference Document for the Technical
Presentation on "National Drug Policies and Management", (WPR/RC28/TP/1) 22 July
1977.
86
Dr. Hye, personal communication, 20 April 1982.
87
Hearing before the Subcommittee on Monopoly of the Select Committee on Small Business,
US Senate, 93rd Congress, Second Session, on Present Status of Competition in the
Pharmaceutical Industry. Evidence sub- mitted by the American Public Health Association
supporting the report on antisubstitution laws (laws requiring a pharmacist not to substitute
a generic equivalent for a product named in a prescription). Quoted by Gish and Feller, 1979,
op.cit.
88
The Daily Telegraph, 3 December 1979, "Drug Factories make one product for sale at two
prices''. Subsequently the Chairman of one of the companies, Arthur H. Cox and Co., wrote
tothe Telegraph supporting the arguments (15 December). But the Chairman of Thomas Kerfoot
and Co. Ltd. wrote retracting his earlier statement that they manufactured Valium and lndocid
on behalf of the brand-name producers.
89
UNIDO, op.cit.
90
WHO, National Policies and Practices in regard to medical products: and rel FVB